Actively Recruiting
Phase 2 Study of Oral Atovaquone for Treating Platinum-Resistant High-Grade Serous Ovarian Cancer in Adult Women
Led by Emory University · Updated on 2025-09-11
28
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating how well atovaquone, a drug normally used to treat certain infections, works in treating patients with platinum-resistant ovarian cancer. This phase II clinical trial aims to assess whether repurposing atovaquone can improve outcomes compared to standard chemotherapy for this hard-to-treat cancer type. The study focuses on patients whose cancer has progressed within six months after their last platinum-based chemotherapy. Participants receive atovaquone orally throughout the study. They also undergo procedures such as computed tomography CT scans, biopsies, or paracentesis to monitor the cancer and treatment effects. After finishing the treatment phase, patients are followed for 30 days and then every six months to track their progress and health. During the trial, researchers will evaluate progression free survival, clinical benefit rate at six months, overall survival, and the impact of atovaquone on specific cancer-related gene activity and immune responses. Safety is monitored by tracking adverse events up to 30 days post-treatment. The total follow-up may last up to one year or more to understand treatment effects over time.
CONDITIONS
Brief Title
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Research Team
N
Namita Khanna, MD, MSPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
